Related Experiment Videos
Serological diagnosis of infectious mononucleosis using three anti-Epstein-Barr virus recombinant ELISAs
I Färber1, P Wutzler, P Wohlrabe
1Institute of Medical Microbiology, Medical Academy, Erfurt, FRG.
Abstract:
A new Epstein-Barr virus (EBV) ELISA system (Biotest Anti-EBV recombinant) was evaluated for usefulness for routine diagnosis of EBV primary infection. The assay system is composed of three different microtest plates coated with three highly purified recombinant EBV antigens. The early antigens p138 (BALF2, truncated) and p54 (BMRF1, whole sequence) are used as a mixture for testing IgM (assay 1) and IgG (assay 2) antibodies. In addition, the EBNA-1 antigen p72 (BKRF1, carboxy-half) is used for detecting IgG antibodies (assay 3). Three panels of sera were examined in direct comparison with standard immunofluorescence (IF): Specimens of (i) 120 infectious mononucleosis (IM) patients, (ii) 60 patients with acute CMV infection, toxoplasmosis or rheumatic disease, respectively, and (iii) 185 healthy blood donors as a control group. 119 IM patients were clearly recognized as having acute primary infection (sensitivity 99.2% compared to VCA-IgM by IF). Three apparently false-positive results were obtained with patients of other diseases and none within the control group (specificity 98.8%). The data suggest that the recombinant ELISA can be used advantageously for standardized rapid diagnosis of acute EBV primary infection.
Insights
A novel Epstein-Barr virus (EBV) ELISA system demonstrates high accuracy for diagnosing primary EBV infections. This recombinant antigen-based assay offers a sensitive and specific tool for routine clinical use.
Area of Science:
- Virology
- Immunology
- Diagnostic Medicine
Background:
- Epstein-Barr virus (EBV) primary infection diagnosis relies on serological methods.
- Standard immunofluorescence (IF) assays are commonly used but can be labor-intensive.
Purpose of the Study:
- To evaluate a new recombinant Epstein-Barr virus (EBV) ELISA system for routine diagnosis of primary EBV infection.
- To assess the sensitivity and specificity of the EBV ELISA compared to standard immunofluorescence (IF).
Main Methods:
- The Biotest Anti-EBV recombinant ELISA system utilizes three microtest plates coated with recombinant EBV antigens (p138, p54, p72).
- Assays were performed for IgM and IgG antibodies against EBV early antigens and EBNA-1.
- Sera from infectious mononucleosis (IM) patients, control patients, and healthy donors were tested and compared to IF results.
Main Results:
- The EBV ELISA correctly identified 119 out of 120 IM patients with acute primary infection (sensitivity 99.2% vs. VCA-IgM by IF).
- The assay showed high specificity, with only three false-positive results among non-EBV patients and none in healthy donors (specificity 98.8%).
Conclusions:
- The recombinant EBV ELISA system is a highly sensitive and specific diagnostic tool.
- This ELISA offers a standardized and rapid method for diagnosing acute EBV primary infections in clinical settings.